摘要
目的观察子宫肌瘤应用不同剂量米非司酮治疗的效果。方法收集我院妇产科2013年1月至2015年12月收治的子宫肌瘤患者110例作为研究对象,随机分为观察组和对照组,每组患者55例。观察组应用低剂量米非司酮治疗(12.5 mg/d),对照组应用常规剂量米非司酮治疗(25.0 mg/d),分别观察两组患者治疗3、6个月的疗效,比较两组患者近、远期疗效。结果两组患者经3个月治疗后,两组治疗总有效率均为76.36%,观察组治疗6个月的总有效率为89.09%,而对照组为87.27%,两组患者同期治疗效果比较无明显差异,但组内治疗6个月和治疗3个月比较有显著差异(P<0.05)。两种药物治疗后瘤体积较治疗前均显著减小(P<0.05)。观察组的不良反应发生率(7.00%)低于对照组(21.80%),差异有统计学意义(P<0.05)。结论 12.5 mg/d米非司酮治疗子宫肌瘤可达到常规剂量治疗疗效,且不良反应较常规剂量少,可在临床推广应用。
Objective To observe the curative effect of different doses of mifepristone in the treatment of uterine myoma. Methods One hundred and ten patients of uterine myoma from January 2013 to December 2015 were randomly divided into observation group and control group, 55 cases in each group. The observation group received low dose mifepristone treatment （12.5 mg/d）; the control group was treated with routine dose of mifepristone treatment （25.0 mg/d）. The curative effect of two groups of patients were observed in 3 months and 6 months respectively, and the short-term and long-term effects of the two groups were compared. Results The total effective rate of the two groups after 3 months was 76.36%, the total effective rate of observation group after 6 months was 89.09%, while the control group was 87.27%, the difference between the two groups was not significant at the same phase （P〉0.05）, but the differences between the curative rate of 3 months and 6 months was significant （P〈0.05）. The tumor volume after treatment of two groups were smaller than before, the difference were significant （P〉0.05）. The adverse reaction rate of the observation group （7.00%） was less than 21.8% of the control group （P〈0.05）. Conclusion 12.5 mg/d mifepristone is not only effective as conventional dose, but also safe, which is worthy clinical application.
出处
《临床医学研究与实践》
2017年第7期86-87,共2页
Clinical Research and Practice
